BIT
BCRX icon

BlackRock Institutional Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

BlackRock Institutional Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$13.2M Buy
2,079,497
+122,927
+6% +$640K ﹤0.01% 2235
2016
Q3 		$8.63M Buy
1,956,570
+102,535
+6% +$410K ﹤0.01% 2422
2016
Q2 		$5.26M Sell
1,854,035
-14,210
-0.8% -$44.1K ﹤0.01% 2658
2016
Q1 		$5.29M Buy
1,868,245
+62,930
+3% +$279K ﹤0.01% 2633
2015
Q4 		$18.6M Buy
1,805,315
+113,053
+7% +$1.12M ﹤0.01% 1922
2015
Q3 		$19.3M Sell
1,692,262
-131,691
-7% -$1.76M ﹤0.01% 1864
2015
Q2 		$27.2M Sell
1,823,953
-89,324
-5% -$1.02M ﹤0.01% 1707
2015
Q1 		$17.3M Buy
1,913,277
+473
+0% +$4.9K ﹤0.01% 2042
2014
Q4 		$23.3M Sell
1,912,804
-19,561
-1% -$216K ﹤0.01% 1805
2014
Q3 		$18.9M Sell
1,932,365
-12,476
-0.6% -$153K ﹤0.01% 1910
2014
Q2 		$24.8M Buy
1,944,841
+865,445
+80% +$8.42M ﹤0.01% 1807
2014
Q1 		$11.4M Sell
1,079,396
-52,256
-5% -$557K ﹤0.01% 2333
2013
Q4 		$8.6M Sell
1,131,652
-33,541
-3% -$212K ﹤0.01% 2505
2013
Q3 		$8.48M Buy
1,165,193
+10,492
+0.9% +$53.2K ﹤0.01% 2462
2013
Q2 		$1.79M Buy
+1,154,701
New +$1.99M ﹤0.01% 3140

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock Institutional Trust's BCRX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its BioCryst Pharmaceuticals (BCRX) stake by 6.3% in Q4 2016, buying an estimated $640K and bringing the position to 2,079,497 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

BlackRock Institutional Trust first reported a position in BCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $27.2M in Q2 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

  • BlackRock Institutional Trust held 2,079,497 shares of BioCryst Pharmaceuticals worth $13.2M as of Q4 2016.
  • BlackRock Institutional Trust bought 122,927 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $640K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2235 holding.
  • BlackRock Institutional Trust first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's BioCryst Pharmaceuticals position peaked at $27.2M in Q2 2015.
  • 112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.